Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A8WP
|
||||
| Former ID |
DNC002788
|
||||
| Drug Name |
6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [551393] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H15N3O
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N
|
||||
| InChI |
1S/C18H15N3O/c19-17(20)14-8-6-13-11-15(9-7-12(13)10-14)18(22)21-16-4-2-1-3-5-16/h1-11H,(H3,19,20)(H,21,22)
|
||||
| InChIKey |
AECPTICWHONWNW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Urokinase-type plasminogen activator | Target Info | Inhibitor | [551393] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| E2F transcription factor network | |||||
| Beta3 integrin cell surface interactions | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| Beta2 integrin cell surface interactions | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| FGF signaling pathway | |||||
| Reactome | Dissolution of Fibrin Clot | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.